Clinical & Commercial Agreement with Kite

March 1, 2019 12:00 PM EST

Released : March 01, 2019 07:00

RNS Number : 5188R
MaxCyte, Inc.
01 March 2019

MaxCyte, Inc.
("MaxCyte" or the "Company")

MaxCyte Announces Multi-Drug Clinical & Commercial Agreement with Kite, a Gilead Company

Gaithersburg, Maryland - 01 March 2019: MaxCyte (LSE: MXCT, MXCS), the global cell-based medicines and life sciences company, announced today that it has expanded its relationship with Kite, a Gilead Company, by entering into a multi-drug clinical and commercial agreement. Under the terms of the agreement, Kite will use MaxCyte's Flow Electroporation® Technology to enable non-viral cell engineering for development of multiple CAR-T drug candidates for up to 10 targets.

"We're excited to take our relationship with Kite further into product development, providing the company the ability to leverage MaxCyte's versatile cell engineering platform to enable the power of gene-editing for clinical and commercial development of critical new CAR-T therapeutics," said Doug Doerfler, President & CEO of MaxCyte, Inc.

The expansion of the Kite-MaxCyte relationship builds on an existing research

agreement announced in November 2018. Under the terms of the new license agreement, Kite obtains non-exclusive clinical and commercial-use rights to MaxCyte's cell engineering platform to develop CAR-T therapies, and MaxCyte will receive development and approval milestones and sales-based payments in addition to other licensing fees.

About MaxCyte

MaxCyte is a clinical-stage global cell-based medicines and life sciences company applying its proprietary cell engineering platform to deliver the advances of cell-based medicine to patients with high unmet medical needs. MaxCyte is developing novel CARMA™ therapies for its own pipeline, with its first drug candidate in a Phase 1 clinical trial. CARMA is MaxCyte's mRNA-based proprietary therapeutic platform for autologous cell therapy for the treatment of solid cancers. In addition, through its core business, MaxCyte leverages its Flow Electroporation® Technology to enable its biopharmaceutical partners to advance the development of innovative medicines, particularly in cell therapy. MaxCyte has placed its flow electroporation instruments worldwide, with all of the top ten global biopharmaceutical companies, has more than 70 partnered program licenses in cell therapy including more than 35 licensed for clinical use. With its robust delivery technology platform, MaxCyte helps its partners to unlock the full potential of their products. For more information, visit www.maxcyte.com.

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014.

For further information, please contact:

MaxCyte Inc. +1 301 944 1660
Doug Doerfler, Chief Executive Officer
Ron Holtz, Chief Financial Officer

Nominated Adviser and Broker
Panmure Gordon +44 (0)20 7886 2500
Emma Earl
Freddy Crossley
Corporate Broking
James Stearns

Financial PR Adviser

Consilium Strategic Communications +44 (0)203 709 5700

Mary-Jane Elliott maxcyte@consilium-comms.com

Chris Welsh

Sukaina Virji

END

AGRLFFEFFFITFIA